CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Curr Atheroscler Rep. 2013 Mar;15(3):311. doi: 10.1007/s11883-013-0311-2.
As coronary artery disease (CAD) still represents the leading cause of death worldwide, more efforts should be made to improve CAD prevention with both lifestyle changes and medical treatment. Elevated blood pressure has been identified as a risk factor for CAD; however, recent evidence suggests that lowering blood pressure too much could be harmful in patients at high cardiovascular risk. Despite the availability of a wide selection of antihypertensive drugs, new strategies and treatments are needed to improve blood pressure control and reduce cardiovascular risk factors associated with elevated blood pressure. New fixed-dose combinations have been recently approved; they usually contain an inhibitor of the renin-angiotensin system, a calcium antagonist and/or a diuretic. Although research and development related to new antihypertensive drugs has slowed in recent years, some new antihypertensive compounds with novel mechanisms of action or dual activity are currently in clinical development.
由于冠状动脉疾病（CAD）仍然是全球范围内的主要死亡原因，因此应该更加努力地通过生活方式改变和药物治疗来改善 CAD 的预防。高血压已被确定为 CAD 的一个危险因素；然而，最近的证据表明，对于心血管风险较高的患者，血压降得过低可能有害。尽管有广泛的降压药物可供选择，但仍需要新的策略和治疗方法来改善血压控制并降低与高血压相关的心血管危险因素。最近批准了新的固定剂量组合；它们通常包含肾素-血管紧张素系统抑制剂、钙拮抗剂和/或利尿剂。尽管近年来与新型降压药物相关的研究和开发有所放缓，但目前一些具有新型作用机制或双重活性的新型降压化合物正在临床开发中。
